What is RVPH's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.00B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for RVPH?

P/E (TTM) is n/a and 52-week range is $0.26 to $15.40 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s RVPH figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for RVPH?

The company profile lists net income (TTM) near -$25M, EPS (TTM) near -$1.92 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Reviva Pharmaceuticals Holdings Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Cupertino, California, US, 13.1M shares outstanding, ISIN US76152G2093 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Reviva Pharmaceuticals Holdings Inc

$RVPH

Health Care · Pharmaceuticals

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the central nervous system, respiratory, and metabolic diseases. The company is headquartered in Cupertino, California and currently employs 14 full-time employees. The company went IPO on 2018-10-18. The firm discovers, develops, and seeks to commercialize therapeutics for diseases representing unmet medical needs. The Company’s pipeline focuses on the central nervous system, inflammatory, and cardiometabolic diseases. Its pipeline includes two drug candidates, brilaroxazine (RP5063) and RP1208. Its lead drug candidate, brilaroxazine, is in clinical development and is to treat multiple neuropsychiatric indications. These include schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), attention-deficit/hyperactivity disorder (ADHD), behavioral and psychotic symptoms of dementia or Alzheimer’s disease (BPSD), and Parkinson’s disease psychosis. Brilaroxazine is also ready for clinical development for two respiratory indications, including pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). Its RP1208 drug candidate is a triple reuptake inhibitor (TRI).

Employees

Website

revivapharma.com/

IPO

2018-10-18

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US76152G2093

Headquarters

Cupertino, California, US

Shares outstanding

13.1M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

15.31%

Browse other companiesFree AI scores and summaries for more stocks